Genetic insight and therapeutic targets in squamous-cell lung cancer

Oncogene

Volumn 31, Issue 46, 2012, Pages 4811-4814

  Sos, M L ^a,b   Thomas, R K ^a,b  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

DDR2; FGFR1; Squamous cell lung cancer

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DASATINIB; DISCOIDIN DOMAIN RECEPTOR 2; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; PROTEIN; RECEPTOR; SORAFENIB; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

APOPTOSIS; BLEEDING; CHROMOSOME 3Q; COPY NUMBER VARIATION; DRUG TARGETING; GENE AMPLIFICATION; GENE FUSION; GENE LOCUS; GENE MUTATION; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS, SQUAMOUS CELL; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, MITOGEN;

ECHINODERMATA; NICOTIANA TABACUM;

EID: 84869497627     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.640     Document Type: Review

References (38)

1. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39:347-351. (Pubitemid 46328493)
2. Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006; 12:852-855. (Pubitemid 44050078)
3. Shendure J, Porreca GJ, Reppas NB, Lin X, McCutcheon JP, Rosenbaum AM et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 2005; 309:1728-1732. (Pubitemid 41285943)
4. Harris TD, Buzby PR, Babcock H, Beer E, Bowers J, Braslavsky I et al. Singlemolecule DNA sequencing of a viral genome. Science 2008; 320:106-109. (Pubitemid 351490765)
5. Lipson D, Raz T, Kieu A, Jones DR, Giladi E, Thayer E et al. Quantification of the yeast transcriptome by single-molecule sequencing. Nat Biotechnol 2009; 27:652-658.
6. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-1068.
7. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311. (Pubitemid 39209661)
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500. (Pubitemid 38720929)
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139. (Pubitemid 38637993)
10. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361:958-967.
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
12. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388.
13. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-566. (Pubitemid 47206930)
14. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
15. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010; 28:4616-4620.
16. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-1531.
17. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550. (Pubitemid 44917502)
18. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:1835-1842.
19. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41:1238-1242.
20. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010; 5: e8960.
21. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 2010; 5: e9112.
22. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 2010; 5: e11022.
23. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2:62ra93.
24. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009; 119:1727-1740.
25. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M et al. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009; 106:18351-18356.
26. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 2009; 75:196-207.
27. Turner NC, Seckl MJ. A therapeutic target for smoking-associated lung cancer. Sci Transl Med 2010; 2:62ps56.
28. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T et al. InhibitorSensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. PLoS One 2011; 6: e20351.
29. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23:18-20. (Pubitemid 29418781)
30. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008; 105:8713-8717. (Pubitemid 351987745)
31. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68:2340-2348. (Pubitemid 351521808)
32. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70:2085-2094.
33. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008; 14:2075-2081. (Pubitemid 351551118)
34. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774-4782.
35. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2009; 10:116-129.
36. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery 2011; 1:78-89.
37. Ikeda K, Wang LH, Torres R, Zhao H, Olaso E, Eng FJ et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem 2002; 277:19206-19212. (Pubitemid 34952488)
38. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:1387-1394.